4D Lifetec secures CHF 23.3 Mio in a share and investment deal with Xlife Sciences opening new horizons in using AI and digital health in early cancer detection.

18.10.2023   In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest™ in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.

Read more...

November 2022 - 4D Lifetec and Molecular Diagnostics Group announce strategic partnership to further industrialization of 4D Lifetest™ liquid biopsy assay

4D Lifetec Ltd. and the German Molecular Diagnostics Group (MDG) announce that they have signed a non-exclusive master collaboration agreement. The goal of the collaboration is to further industrialize the 4D Lifetest™, a novel blood test for the early detection of cancer. Planned joint projects include industrial production of the assay kits and automation of the 4D Lifetest™ wetlab workflow to unlock its high-throughput potential for screening applications. 

Read more...

June 2022 - Press Release: 4D Lifetec announces successful first closing of CHF 1.9 million Series B financing to launch its early lung cancer detection liquid biopsy assay 4D Lifetest™ Lung Dx in Europe.

4D Lifetec AG, a privately-held Swiss diagnostics company focusing on the development and marketing of early stage liquid biopsy cancer diagnostics, announced today that it has raised CHF 1.9 million in a first closing of its Series B round.

 

To read the press release click here.

Read more...

November 2020 - 4D Lifetec publishes first clinical results at the 39th World Cancer Conference

In an observational study 'Prospective Evaluation of 4D LifetestTM Parameters to Develop a Universal Early Cancer Diagnosis Test', blood samples from 39 participants were collected (49% patients with newly diagnosed, untreated lung cancer and 51% non-cancer). Evaluation of our DDS biomarker (DNA Damage Sensitivity) comparing non-cancer with cancer samples resulted in more than 90% sensitivity at 95% specificity (95% CI: 76.4-99.7%) across all stages.

Read more...